Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95


64Cu-ATSM/64Cu-Cl2 and their relationship to hypoxia in glioblastoma: a preclinical study.

Pérès EA, Toutain J, Paty LP, Divoux D, Ibazizène M, Guillouet S, Barré L, Vidal A, Cherel M, Bourgeois M, Bernaudin M, Valable S.

EJNMMI Res. 2019 Dec 19;9(1):114. doi: 10.1186/s13550-019-0586-6.


An image-based mapping of significance and relevance of facial skin colour changes of females living in Thailand.

Séroul P, Campiche R, Gougeon S, Cherel M, Rawlings AV, Voegeli R.

Int J Cosmet Sci. 2020 Feb;42(1):99-107. doi: 10.1111/ics.12593. Epub 2019 Dec 25.


Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture.

Bailly C, Bodet-Milin C, Bourgeois M, Gouard S, Ansquer C, Barbaud M, Sébille JC, Chérel M, Kraeber-Bodéré F, Carlier T.

Cancers (Basel). 2019 Aug 31;11(9). pii: E1282. doi: 10.3390/cancers11091282. Review.


TE1PA as Innovating Chelator for 64Cu Immuno-TEP Imaging: A Comparative in Vivo Study with DOTA/NOTA by Conjugation on 9E7.4 mAb in a Syngeneic Multiple Myeloma Model.

Navarro AS, Le Bihan T, Le Saëc P, Bris NL, Bailly C, Saï-Maurel C, Bourgeois M, Chérel M, Tripier R, Faivre-Chauvet A.

Bioconjug Chem. 2019 Sep 18;30(9):2393-2403. doi: 10.1021/acs.bioconjchem.9b00510. Epub 2019 Aug 22.


Potential for Nuclear Medicine Therapy for Glioblastoma Treatment.

Bailly C, Vidal A, Bonnemaire C, Kraeber-Bodéré F, Chérel M, Pallardy A, Rousseau C, Garcion E, Lacoeuille F, Hindré F, Valable S, Bernaudin M, Bodet-Milin C, Bourgeois M.

Front Pharmacol. 2019 Jul 10;10:772. doi: 10.3389/fphar.2019.00772. eCollection 2019. Review.


Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives.

Lepareur N, Lacœuille F, Bouvry C, Hindré F, Garcion E, Chérel M, Noiret N, Garin E, Knapp FFR Jr.

Front Med (Lausanne). 2019 Jun 14;6:132. doi: 10.3389/fmed.2019.00132. eCollection 2019. Review.


Hypoxia Imaging and Adaptive Radiotherapy: A State-of-the-Art Approach in the Management of Glioma.

Gérard M, Corroyer-Dulmont A, Lesueur P, Collet S, Chérel M, Bourgeois M, Stefan D, Limkin EJ, Perrio C, Guillamo JS, Dubray B, Bernaudin M, Thariat J, Valable S.

Front Med (Lausanne). 2019 Jun 12;6:117. doi: 10.3389/fmed.2019.00117. eCollection 2019. Review.


What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model.

Bailly C, Gouard S, Guérard F, Chalopin B, Carlier T, Faivre-Chauvet A, Remaud-Le Saëc P, Bourgeois M, Chouin N, Rbah-Vidal L, Tripier R, Haddad F, Kraeber-Bodéré F, Bodet-Milin C, Chérel M.

Int J Mol Sci. 2019 May 24;20(10). pii: E2564. doi: 10.3390/ijms20102564.


FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P.

Cytokine. 2019 Aug;120:85-87. doi: 10.1016/j.cyto.2019.04.015. Epub 2019 Apr 28.


Interest of Pet Imaging in Multiple Myeloma.

Jamet B, Bailly C, Carlier T, Touzeau C, Nanni C, Zamagni E, Barré L, Michaud AV, Chérel M, Moreau P, Bodet-Milin C, Kraeber-Bodéré F.

Front Med (Lausanne). 2019 Apr 9;6:69. doi: 10.3389/fmed.2019.00069. eCollection 2019. Review.



Koumeir C, De Nadal V, Cherubini R, Cherel M, Garrido E, Gouard S, Guertin A, Haddad F, Métivier V, Michel N, Poirier F, Servagent N, Sounalet T, Varmenot N.

Radiat Prot Dosimetry. 2019 May 1;183(1-2):270-273. doi: 10.1093/rpd/ncy301.


FLT3 ligand plasma levels in acute myeloid leukemia.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P.

Haematologica. 2019 Jun;104(6):e240-e243. doi: 10.3324/haematol.2018.209460. Epub 2019 Jan 10. No abstract available.


Prosthetic groups for radioiodination and astatination of peptides and proteins: A comparative study of five potential bioorthogonal labeling strategies.

Navarro L, Berdal M, Chérel M, Pecorari F, Gestin JF, Guérard F.

Bioorg Med Chem. 2019 Jan 1;27(1):167-174. doi: 10.1016/j.bmc.2018.11.034. Epub 2018 Nov 26.


Plasmacytoma-like post-kidney-transplant lymphoproliferative disorder confined to renal allograft and urinary tract: A case report.

Thibaud V, Rivalan J, Llamas F, Cherel M, Decaux O, Vigneau C.

Nephrol Ther. 2018 Dec;14(7):544-547. doi: 10.1016/j.nephro.2018.07.404. Epub 2018 Oct 6.


Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with 18FDG PET-CT.

Foubert F, Gouard S, Saï-Maurel C, Chérel M, Faivre-Chauvet A, Goldenberg DM, Barbet J, Bailly C, Bodet-Milin C, Carlier T, Kraeber-Bodéré F, Touchefeu Y, Frampas E.

Oncotarget. 2018 Jun 8;9(44):27502-27513. doi: 10.18632/oncotarget.25514. eCollection 2018 Jun 8.


Synthesis of C-functionalized TE1PA and comparison with its analogues. An example of bioconjugation on 9E7.4 mAb for multiple myeloma 64Cu-PET imaging.

Le Bihan T, Navarro AS, Le Bris N, Le Saëc P, Gouard S, Haddad F, Gestin JF, Chérel M, Faivre-Chauvet A, Tripier R.

Org Biomol Chem. 2018 Jun 13;16(23):4261-4271. doi: 10.1039/c8ob00499d.


Alphatherapy, the new impetus to targeted radionuclide therapy?

Chatal JF, Kraeber-Bodéré F, Chérel M, Haddad F.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1362-1363. doi: 10.1007/s00259-018-4026-z. No abstract available.


Delivery of DTPA through Liposomes as a Good Strategy for Enhancing Plutonium Decorporation Regardless of Treatment Regimen.

Grémy O, Miccoli L, Lelan F, Bohand S, Cherel M, Mougin-Degraef M.

Radiat Res. 2018 May;189(5):477-489. doi: 10.1667/RR14968.1. Epub 2018 Mar 12.


Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma.

Bailly C, Gouard S, Lacombe M, Remaud-Le Saëc P, Chalopin B, Bourgeois M, Chouin N, Tripier R, Halime Z, Haddad F, Faivre-Chauvet A, Kraeber-Bodéré F, Chérel M, Bodet-Milin C.

Oncotarget. 2018 Jan 3;9(10):9061-9072. doi: 10.18632/oncotarget.23886. eCollection 2018 Feb 6.


Bifunctional aryliodonium salts for highly efficient radioiodination and astatination of antibodies.

Guérard F, Navarro L, Lee YS, Roumesy A, Alliot C, Chérel M, Brechbiel MW, Gestin JF.

Bioorg Med Chem. 2017 Nov 1;25(21):5975-5980. doi: 10.1016/j.bmc.2017.09.022. Epub 2017 Sep 19.


Radioimmunoconjugates for treating cancer: recent advances and current opportunities.

Bourgeois M, Bailly C, Frindel M, Guerard F, Chérel M, Faivre-Chauvet A, Kraeber-Bodéré F, Bodet-Milin C.

Expert Opin Biol Ther. 2017 Jul;17(7):813-819. doi: 10.1080/14712598.2017.1322577. Epub 2017 May 4. Review.


A new discrepancy of HPA-3 genotyping because of a rare HPA-27bw polymorphism.

Bertrand G, Aarnink A, Nivet C, Jacques A, Cherel M, Renac V, Kennel A.

Transfus Med. 2017 Aug;27(4):307-308. doi: 10.1111/tme.12414. Epub 2017 Apr 17. No abstract available.


PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients.

Bailly C, Leforestier R, Jamet B, Carlier T, Bourgeois M, Guérard F, Touzeau C, Moreau P, Chérel M, Kraeber-Bodéré F, Bodet-Milin C.

Int J Mol Sci. 2017 Feb 18;18(2). pii: E445. doi: 10.3390/ijms18020445. Review.


Editorial: Innovative Radiopharmaceuticals in Oncology and Neurology.

Barbet J, Arlicot N, Gaugler MH, Chérel M, Guilloteau D, Kraeber-Bodéré F.

Front Med (Lausanne). 2017 Jan 11;3:74. doi: 10.3389/fmed.2016.00074. eCollection 2016. No abstract available.


Immuno-PET for Clinical Theranostic Approaches.

Bailly C, Cléry PF, Faivre-Chauvet A, Bourgeois M, Guérard F, Haddad F, Barbet J, Chérel M, Kraeber-Bodéré F, Carlier T, Bodet-Milin C.

Int J Mol Sci. 2016 Dec 28;18(1). pii: E57. doi: 10.3390/ijms18010057. Review.


ImmunoPET to help stratify patients for targeted therapies and to improve drug development.

Kraeber-Bodere F, Bailly C, Chérel M, Chatal JF.

Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2166-2168. Epub 2016 Aug 18. No abstract available.


Novel approaches to characterize age-related remodelling of the dermal-epidermal junction in 2D, 3D and in vivo.

Newton VL, Bradley RS, Seroul P, Cherel M, Griffiths CE, Rawlings AV, Voegeli R, Watson RE, Sherratt MJ.

Skin Res Technol. 2017 May;23(2):131-148. doi: 10.1111/srt.12312. Epub 2016 Aug 9.


[Alpha-Radioimmunotherapy: principle and relevance in anti-tumor immunity].

Ménager J, Gorin JB, Fichou N, Gouard S, Morgenstern A, Bruchertseifer F, Davodeau F, Kraeber-Bodéré F, Chérel M, Gaschet J, Guilloux Y.

Med Sci (Paris). 2016 Apr;32(4):362-9. doi: 10.1051/medsci/20163204014. Epub 2016 May 2. Review. French.


Production and characterization of monoclonal antibodies specific for canine CD138 (syndecan-1) for nuclear medicine preclinical trials on spontaneous tumours.

Diab M, Nguyen F, Berthaud M, Maurel C, Gaschet J, Verger E, Ibisch C, Rousseau C, Chérel M, Abadie J, Davodeau F.

Vet Comp Oncol. 2017 Sep;15(3):932-951. doi: 10.1111/vco.12233. Epub 2016 Apr 14.


(211)At-labeled agents for alpha-immunotherapy: On the in vivo stability of astatine-agent bonds.

Ayed T, Pilmé J, Tézé D, Bassal F, Barbet J, Chérel M, Champion J, Maurice R, Montavon G, Galland N.

Eur J Med Chem. 2016 Jun 30;116:156-164. doi: 10.1016/j.ejmech.2016.03.082. Epub 2016 Mar 29.


Correction: New synthesis of phenyl-isothiocyanate C-functionalised cyclams. Bioconjugation and (64)Cu phenotypic PET imaging studies of multiple myeloma with the te2a derivative.

Halime Z, Frindel M, Camus N, Orain PY, Lacombe M, Bernardeau K, Chérel M, Gestin JF, Faivre-Chauvet A, Tripier R.

Org Biomol Chem. 2016 Apr 12;14(15):3838. doi: 10.1039/c6ob90046a.


Long-Term Toxicity of 213Bi-Labelled BSA in Mice.

Dorso L, Bigot-Corbel E, Abadie J, Diab M, Gouard S, Bruchertseifer F, Morgenstern A, Maurel C, Chérel M, Davodeau F.

PLoS One. 2016 Mar 16;11(3):e0151330. doi: 10.1371/journal.pone.0151330. eCollection 2016.


Radioimmunotherapy for Treatment of Acute Leukemia.

Bodet-Milin C, Kraeber-Bodéré F, Eugène T, Guérard F, Gaschet J, Bailly C, Mougin M, Bourgeois M, Faivre-Chauvet A, Chérel M, Chevallier P.

Semin Nucl Med. 2016 Mar;46(2):135-46. doi: 10.1053/j.semnuclmed.2015.10.007. Review.


Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis.

Derrien A, Gouard S, Maurel C, Gaugler MH, Bruchertseifer F, Morgenstern A, Faivre-Chauvet A, Classe JM, Chérel M.

Front Med (Lausanne). 2015 Dec 21;2:88. doi: 10.3389/fmed.2015.00088. eCollection 2015.


(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.

Chevallier P, Eugene T, Robillard N, Isnard F, Nicolini F, Escoffre-Barbe M, Huguet F, Hunault M, Marcais A, Gaschet J, Cherel M, Guillaume T, Delaunay J, Peterlin P, Eveillard M, Thomas X, Ifrah N, Lapusan S, Bodet-Milin C, Barbet J, Faivre-Chauvet A, Ferrer L, Bene MC, Le Houerou C, Goldenberg DM, Wegener WA, Kraeber-Bodéré F.

Lancet Haematol. 2015 Mar;2(3):e108-17. doi: 10.1016/S2352-3026(15)00020-4. Epub 2015 Feb 25.


Early Postnatal Myelin Content Estimate of White Matter via T1w/T2w Ratio.

Lee K, Cherel M, Budin F, Gilmore J, Consing KZ, Rasmussen J, Wadhwa PD, Entringer S, Glasser MF, Van Essen DC, Buss C, Styner M.

Proc SPIE Int Soc Opt Eng. 2015;9417. pii: 94171R. Epub 2015 Mar 17.


Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model.

Fichou N, Gouard S, Maurel C, Barbet J, Ferrer L, Morgenstern A, Bruchertseifer F, Faivre-Chauvet A, Bigot-Corbel E, Davodeau F, Gaschet J, Chérel M.

Front Med (Lausanne). 2015 Nov 4;2:76. doi: 10.3389/fmed.2015.00076. eCollection 2015.


Alpha Particles Induce Autophagy in Multiple Myeloma Cells.

Gorin JB, Gouard S, Ménager J, Morgenstern A, Bruchertseifer F, Faivre-Chauvet A, Guilloux Y, Chérel M, Davodeau F, Gaschet J.

Front Med (Lausanne). 2015 Oct 19;2:74. doi: 10.3389/fmed.2015.00074. eCollection 2015.


New synthesis of phenyl-isothiocyanate C-functionalised cyclams. Bioconjugation and (64)Cu phenotypic PET imaging studies of multiple myeloma with the te2a derivative.

Halime Z, Frindel M, Camus N, Orain PY, Lacombe M, Bernardeau K, Chérel M, Gestin JF, Faivre-Chauvet A, Tripier R.

Org Biomol Chem. 2015 Dec 14;13(46):11302-14. doi: 10.1039/c5ob01618e. Erratum in: Org Biomol Chem. 2016 Apr 12;14(15):3838. Bernardeau, Karine [Added].


Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging.

Colombié M, Gouard S, Frindel M, Vidal A, Chérel M, Kraeber-Bodéré F, Rousseau C, Bourgeois M.

Front Med (Lausanne). 2015 Aug 24;2:58. doi: 10.3389/fmed.2015.00058. eCollection 2015. Review.


Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction.

Ménager J, Gorin JB, Maurel C, Drujont L, Gouard S, Louvet C, Chérel M, Faivre-Chauvet A, Morgenstern A, Bruchertseifer F, Davodeau F, Gaschet J, Guilloux Y.

PLoS One. 2015 Jun 22;10(6):e0130249. doi: 10.1371/journal.pone.0130249. eCollection 2015.


Automatic Tissue Segmentation of Neonate Brain MR Images with Subject-specific Atlases.

Cherel M, Budin F, Prastawa M, Gerig G, Lee K, Buss C, Lyall A, Consing KZ, Styner M.

Proc SPIE Int Soc Opt Eng. 2015 Feb 21;9413. doi: 10.1117/12.2082209.


Using α radiation to boost cancer immunity?

Gorin JB, Guilloux Y, Morgenstern A, Chérel M, Davodeau F, Gaschet J.

Oncoimmunology. 2014 Dec 13;3(9):e954925. eCollection 2014 Oct.


New beam monitoring tool for radiobiology experiments at the cyclotron ARRONAX.

Schwob L, Koumeir C, Servagent N, Cherel M, Guertin A, Haddad F, Métivier V, Michel N, Poirier F, Rahmani A, Varmenot N.

Radiat Prot Dosimetry. 2015 Sep;166(1-4):257-60. doi: 10.1093/rpd/ncv199. Epub 2015 Apr 20.


Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy?

Guerard F, Barbet J, Chatal JF, Kraeber-Bodere F, Cherel M, Haddad F.

Q J Nucl Med Mol Imaging. 2015 Jun;59(2):161-7. Epub 2015 Mar 10. Review.


Assessment of a fully 3D Monte Carlo reconstruction method for preclinical PET with iodine-124.

Moreau M, Buvat I, Ammour L, Chouin N, Kraeber-Bodéré F, Chérel M, Carlier T.

Phys Med Biol. 2015 Mar 21;60(6):2475-91. doi: 10.1088/0031-9155/60/6/2475. Epub 2015 Mar 5.


Tumor immunotargeting using innovative radionuclides.

Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Mathieu C, Guérard F, Frampas E, Carlier T, Chouin N, Haddad F, Chatal JF, Faivre-Chauvet A, Chérel M, Barbet J.

Int J Mol Sci. 2015 Feb 11;16(2):3932-54. doi: 10.3390/ijms16023932. Review.


Syndecan-1 regulates the biological activities of interleukin-34.

Segaliny AI, Brion R, Mortier E, Maillasson M, Cherel M, Jacques Y, Le Goff B, Heymann D.

Biochim Biophys Acta. 2015 May;1853(5):1010-21. doi: 10.1016/j.bbamcr.2015.01.023. Epub 2015 Feb 4.


Radioimmunoconjugates for the treatment of cancer.

Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Eugène T, Pallardy A, Frampas E, Carlier T, Ferrer L, Gaschet J, Davodeau F, Gestin JF, Faivre-Chauvet A, Barbet J, Chérel M.

Semin Oncol. 2014 Oct;41(5):613-22. doi: 10.1053/j.seminoncol.2014.07.004. Epub 2014 Jul 22. Review.


Antitumor immunity induced after α irradiation.

Gorin JB, Ménager J, Gouard S, Maurel C, Guilloux Y, Faivre-Chauvet A, Morgenstern A, Bruchertseifer F, Chérel M, Davodeau F, Gaschet J.

Neoplasia. 2014 Apr;16(4):319-28. doi: 10.1016/j.neo.2014.04.002.

Supplemental Content

Loading ...
Support Center